Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
India business continues to outperform market growth with 12-13% revenue growth YTD; focus on cardiac, diabetes, and gastro drives growth. Operating EBITDA margin expected to sustain at about 32.5% in Q4 FY25.
From Torrent Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- India business continues to outperform market growth with 12-13% revenue growth YTD; focus on cardiac, diabetes, and gastro drives growth.
- Chronic business in India grew 14% vs. IPM 10%, aided by new product launches and expanded field force.
- Brazil market expected to maintain double-digit growth (~10-12% constant currency); government price hikes anticipated to offset currency depreciation.
- Germany business to see growth from new tenders starting Q2 next year; expect continued high single-digit growth.
- US business stable but slow pickup expected short-term; growth dependent on new ANDA filings.
- Overall, company projects 7% underlying revenue growth normalized for insulin business and currency impact in Q3.
2 more points from Torrent Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Torrent Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sudhir Menon mentioned that the company's capital allocation priorities and strategic investments are still a work in progress, with specific details expected in a couple of quarters.
- The top priority for capital allocation remains India, especially branded generics, where the company has the best track record and highest comfort.
- They remain open to opportunities in developed markets like Germany and the US in specified areas.
- There was mention of reinvestment happening in the branded business which could impact margin improvements, indicating ongoing or planned investments.
2 more points from Torrent Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Torrent Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The document does not explicitly mention the current or expected order book or pending orders for Torrent Pharmaceuticals.
- However, highlights on product launches and market expectations are noted:
- In Brazil and India, plans to launch GLP-1 products are aligned with patent expiry in March 2026, aiming to be in the first wave of launches.
- Brazil has a rich pipeline of 20 molecules filed and awaiting ANVISA approval.
- Germany business won incremental new tenders starting to contribute from Q2 FY26.
2 more points from Torrent Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Torrent Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹4.2K Cr, net profit ₹364 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Torrent Pharmaceuticals Ltd's management said in earlier quarters
- Q4 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Arthneeti Pro · Annual
Torrent Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Torrent Pharmaceuticals Ltd Q3 FY25 results?
India business continues to outperform market growth with 12-13% revenue growth YTD; focus on cardiac, diabetes, and gastro drives growth. Operating EBITDA margin expected to sustain at about 32.5% in Q4 FY25.
What is Torrent Pharmaceuticals Ltd share price analysis?
Torrent Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 82.4 with a market cap of ₹183,832 Cr. Investors should review the full earnings analysis for detailed insights.
Is Torrent Pharmaceuticals Ltd planning capital expenditure?
Sudhir Menon mentioned that the company's capital allocation priorities and strategic investments are still a work in progress, with specific details expected in a couple of quarters.
Keep Torrent Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.